Trius Therapeutics LLC clinical trials

Acquired by Merck & Co., Inc, Jan 21, 2015 · source ↗

The registry lists 19 studies whose lead sponsor is Trius Therapeutics LLC. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 25, 2019.

Studies

Recruiting first, then most recently updated. Showing 19 of 19. All Merck & Co., Inc studies →

• Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure InfectionsCompletedNCT00761215Phase 2

  Sponsor listed in the registry: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Trius Therapeutics LLC became part of Merck & Co., Inc

• Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male SubjectsCompletedNCT01442831Phase 1

  Sponsor listed in the registry: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Trius Therapeutics LLC became part of Merck & Co., Inc

• Microdialysis and Pharmacokinetic Study of TR-701CompletedNCT00666601Phase 1

  Sponsor listed in the registry: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Trius Therapeutics LLC became part of Merck & Co., Inc

• Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mgCompletedNCT01271998Phase 1

  Sponsor listed in the registry: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Trius Therapeutics LLC became part of Merck & Co., Inc

• Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent PatientsCompletedNCT01156077Phase 1

  Sponsor listed in the registry: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Trius Therapeutics LLC became part of Merck & Co., Inc

• A Thorough QT Study of TR-701free Acid (FA) in Healthy SubjectsCompletedNCT01461460Phase 1

  Sponsor listed in the registry: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Trius Therapeutics LLC became part of Merck & Co., Inc

• TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsCompletedNCT01421511Phase 3

  Sponsor listed in the registry: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Trius Therapeutics LLC became part of Merck & Co., Inc

• A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA StudyCompletedNCT01519778Phase 2

  Sponsor listed in the registry: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Trius Therapeutics LLC became part of Merck & Co., Inc

• TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.CompletedNCT01170221Phase 3

  Sponsor listed in the registry: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Trius Therapeutics LLC became part of Merck & Co., Inc

• A Phase 1 Crossover Study of Blood Pressure and Heart Rate ResponseCompletedNCT01577459Phase 1

  Sponsor listed in the registry: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Trius Therapeutics LLC became part of Merck & Co., Inc

• Food Effects of Single Oral Dose of 600mg TR-701CompletedNCT00671359Phase 1

  Sponsor listed in the registry: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Trius Therapeutics LLC became part of Merck & Co., Inc

• A Phase 1, Open-Label, 10 Day Safety StudyCompletedNCT01623401Phase 1

  Sponsor listed in the registry: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Trius Therapeutics LLC became part of Merck & Co., Inc

• Pharmacokinetics, Safety, and Tolerability of TR-701 Free Acid (FA) in Elderly SubjectsCompletedNCT01496677Phase 1

  Sponsor listed in the registry: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Trius Therapeutics LLC became part of Merck & Co., Inc

• Single and Multiple Ascending Dose Pharmacokinetic Study of TR701 in Healthy AdultsCompletedNCT00671814Phase 1

  Sponsor listed in the registry: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Trius Therapeutics LLC became part of Merck & Co., Inc

• A PK and Safety Study in Subjects With Hepatic ImpairmentCompletedNCT01431833Phase 1

  Sponsor listed in the registry: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Trius Therapeutics LLC became part of Merck & Co., Inc

• Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)CompletedNCT00983255Phase 1

  Sponsor listed in the registry: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Trius Therapeutics LLC became part of Merck & Co., Inc

• A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine ChallengeCompletedNCT01539473Phase 1

  Sponsor listed in the registry: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Trius Therapeutics LLC became part of Merck & Co., Inc

• Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of Torezolid PhosphateCompletedNCT00876655Phase 1

  Sponsor listed in the registry: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Trius Therapeutics LLC became part of Merck & Co., Inc

• A Pharmacokinetics and Safety Study in Subjects With Renal ImpairmentCompletedNCT01452828Phase 1

  Sponsor listed in the registry: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Trius Therapeutics LLC became part of Merck & Co., Inc